vitamin-k-1 and Skin-Diseases

Topical application of Vitamin K1 has been demonstrated to effectively treat papulopustular skin rash, a serious and frequently encountered side effect of Epidermal Growth Factor Inhibitors (EGFRIs). Systemic absorption of vitamin K1 from skin and the resultant consequence of antagonizing EGFRIs anticancer effects jeopardizes the clinical acceptability of this rather effective treatment. The purpose of the present study was to rationally formulate and evaluate the release rate and transdermal absorption of a wide range of Vitamin K1 dermal preparations with a variety of physiochemical properties. A library of 33 formulations with were compounded and tested for Vitamin K1 permeation using hydrophobic membranes and porcine skin mounted in a Fran diffusion cells. Our results demonstrate the lowest diffusion for water-in-oil emulsions, which also demonstrated a negligible transdermal absorption. The statistical analysis showed a significant correlation between in vitro and ex vivo results. While viscosity did not have a significant impact on the diffusion or absorption of vitamin K1, an increase in the lipid content was correlated with an increase in transmembrane diffusion (not with transdermal absorption). Overall, formulation design significantly impacts the release rate and transdermal absorption of vitamin K1, and confirms the possibility of minimal systemic distribution of this vitamin for this specific purpose.

Topics: Administration, Topical; Animals; Antineoplastic Agents; Dermatologic Agents; Diffusion; Emulsions; Gels; In Vitro Techniques; Lipids; Membranes, Artificial; Ointments; Skin; Skin Absorption; Skin Cream; Skin Diseases; Surface-Active Agents; Sus scrofa; Viscosity; Vitamin K 1; Water

For the post laser treatment of couperosis a new dermal formulation was developed combining three actives: vitamin K1, A1 and rutin, where both vitamins were incorporated into solid lipid nanoparticles (SLN) and the poorly soluble antioxidant rutin formulated as nanocrystal. All three formulations were stable over 6 months either on their own or after their incorporation into a hydrogel. Vitamin A1 at 0.3% in emulsions shows local skin irritation due to very rapid release. By forming SLN, prolonged release with less irritation potential but deeper penetration was achieved in porcine ear skin. Due to the nanosized rutin, the new hydrogel showed clearly increased antioxidant activity, representing a stronger protection potential against reactive oxygen species (ROS), compared to marketed anti-redness products with rutin as raw drug powder or water-soluble derivative. In addition, rutin nanocrystals showed up to 5 times pronounced penetration compared to μm-sized raw drug powder. The orientating in-vivo case study revealed a three to six times faster recovery after laser treatment of couperosis by twice daily application of the new hydrogel, regarding scabbed-over areas and erythema. Continued use of the new gel also showed preventive properties against recurrences of veins for at least 8 month.

Topics: Administration, Cutaneous; Animals; Drug Carriers; Drug Therapy, Combination; Humans; Male; Nanoparticles; Rutin; Skin Absorption; Skin Diseases; Swine; Treatment Outcome; Vitamin A; Vitamin K 1

To discuss the impact of 0.1% vitamin K1 (VitK1) cream on cetuximab-induced skin toxicity for colorectal cancer patients. 60 colorectal cancer patients with cetuximab therapy after hospitalization, were divided into experimental group (Ward A) and control group (Ward B) according to personnel sequential number, with 30 cases in each group. Routine nursing was implemented on control group. For experimental group, on the routine nursing basis, 0.1% VitK1 cream was smeared on face, neck, chest, back and nail (toenail) edge with three times one day at the application of cetuximab day. After cetuximab applied in 8 weeks, both skin itch and dry skin for patients in experimental group were significantly improved compared those in control group, showing statistically significant difference (W=708.000, P=0.001: W=662. 500, P=0.000). 0.1% VitK1 cream was conducive to improve both skin itch and dry skin symptoms in the cetuximab-induced skin toxicity for colorectal cancer patients.

Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Ointments; Skin; Skin Diseases; Vitamin K 1

Topics: Antifibrinolytic Agents; Female; Humans; Hypersensitivity, Delayed; Male; Middle Aged; Patch Tests; Skin Diseases; Vitamin K 1

Topics: Adult; Antigens; Blood Proteins; Factor X; Female; Glycoproteins; Heterozygote; Humans; Male; Necrosis; Penile Diseases; Protein C; Skin Diseases; Vitamin K 1; Warfarin

Successful prevention of the progression of incipient hemorrhagic skin necrosis by timely administration of vitamin K1 in a woman treated with phenprocoumon is presented. From a critical review of the literature strong evidence emerges that coumarin necrosis does only occur in cases with severe initial drug induced hypocoagulability. Non- recognition thusfar of its importance is due to insufficient knowledge of the biological activities of thromboplastin preparations presently used in the laboratory control of oral anticoagulation. All well documented cases with apparently adequate Quick values were monitored with Faktor VIII insensitive thromboplastin. Therefore, such preparations should no longer be used in anticoagulant control.

Topics: 4-Hydroxycoumarins; Female; Hemorrhage; Humans; Middle Aged; Necrosis; Phenprocoumon; Skin; Skin Diseases; Thromboplastin; Vitamin K 1

Topics: Administration, Topical; Anti-Inflammatory Agents; Antifungal Agents; Candidiasis; Diagnosis, Differential; Diaper Rash; Female; Glucocorticoids; Granuloma; Humans; Infant; Male; Sarcoma, Kaposi; Skin Diseases; Skin Neoplasms; Vitamin K 1

Topics: Adolescent; Adrenal Cortex Hormones; Adult; Female; Humans; Male; Middle Aged; Skin Diseases; Vitamin K 1